Jimandin

Sitagliptin, the active ingredient in Jimandin, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral dosage form for oral administration. It improves glycaemic control by enhancing insulin secretion and reducing glucagon release in adults with type 2 diabetes mellitus, and is used as part of a comprehensive diabetes management plan.

GNH USA supplies Jimandin as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide through regulated wholesale channels and supporting customers with quality assurance, regulatory documentation and reliable logistics.

Jimandin (sitagliptin) is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves glycaemic control when combined with diet and exercise. - Adjunct therapy: added to other antidiabetic agents to achieve target HbA1c. - Monotherapy: can be prescribed alone for patients inadequately controlled by lifestyle alone.

Sitagliptin may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Headache - Upper respiratory tract infection - Nasopharyngitis

Serious or Rare Side Effects: - Pancreatitis - Severe allergic reactions (anaphylaxis) - Joint pain (arthralgia)

When prescribing Jimandin, clinicians should consider several safety precautions to minimise risk. - Renal function: assess before initiating and monitor periodically, especially in patients with impaired clearance. - Hepatic function: use with caution in patients with liver disease and monitor liver enzymes. - History of pancreatitis: avoid or use only with careful monitoring due to potential recurrence. - Concomitant insulin or sulfonylureas: monitor for hypoglycaemia and adjust doses as needed. - Pregnancy and lactation: safety not established; weigh benefits against potential risks before use. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Sitagliptin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may increase sitagliptin exposure and risk of adverse effects. - Co‑administration with insulin secretagogues (e.g., sulfonylureas): may heighten risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of sitagliptin; monitor renal function. - ACE inhibitors or ARBs: monitor blood pressure as combined effects may occur. - Use with other DPP‑4 inhibitors: not recommended due to additive pharmacologic activity.